Ulrich Steidl, M.D., Ph.D., Distinguished Leader in Hematologic Research, Joins Esteemed Association of American Physicians
Ulrich Steidl, M.D., Ph.D., a pioneering investigator in the molecular and cellular basis of blood disorders, has been inducted into the prestigious Association of American Physicians (AAP). This venerable institution, with a legacy spanning nearly a century and a half, represents the pinnacle of physician-scientist excellence, honoring those whose research innovation profoundly advances medical science. Dr. Steidl serves as professor and chair of cell biology at the Albert Einstein College of Medicine and acts as deputy director at the Montefiore Einstein Comprehensive Cancer Center, a National Cancer Institute (NCI)-designated facility renowned for its research and clinical care.
The announcement, made on April 26, recognizes Dr. Steidl’s exemplary contributions to understanding the pathogenesis of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), two hematologic malignancies with complex stem cell origins. His election to the AAP underscores his stature as a leader synthesizing basic molecular insights with translational strategies aimed at improving patient outcomes. According to the AAP, membership is conferred upon individuals who demonstrate exceptional physician-led scientific leadership and groundbreaking research accomplishments.
At the heart of Dr. Steidl’s research lies a profound investigation into the biology of hematopoietic stem cells that give rise to MDS and ultimately AML. His work, driven by robust NIH and private funding, delves into the molecular abnormalities within pre-leukemic stem cells — the precursors to malignant clones. By elucidating the cellular pathways and genetic alterations underpinning the transition from pre-leukemic to full leukemic states, Dr. Steidl has charted pathways that are critical for early intervention and targeted therapy development. This insight is shifting paradigms in hematologic oncology, moving from symptom management to molecularly precise disruption of disease progression.
Significantly, Dr. Steidl was among the first researchers to demonstrate the defective nature of hematopoietic stem cells in MDS, a disorder recognized as a precursor to AML. This conceptual breakthrough, published in high-impact journals such as Nature Medicine, revolutionized the understanding of how these diseases originate and evolve at the stem cell level, challenging previously accepted models. Through this work, he has laid the foundation for novel therapeutic agents currently undergoing clinical trials, aiming to eradicate the aberrant stem cell populations that drive disease perpetuation and relapse.
The translational arc of Dr. Steidl’s research is underscored by his receipt of the National Cancer Institute’s Outstanding Investigator Award in 2021 — a competitive grant that supports sustained, innovative research endeavors. This award, accompanied by a seven-year funding commitment of $7 million, enables his laboratory to probe deeper into the genetic and epigenetic mechanisms governing stem cell transformation. It also facilitates the development and testing of drug candidates designed to selectively target malignant stem cells without compromising normal hematopoiesis, a critical balance in preventing treatment-related toxicity.
In addition to his laboratory investigations, Dr. Steidl holds the Edward P. Evans Endowed Professorship for Myelodysplastic Syndromes and serves as interim director of the Ruth L. and David S. Gottesman Institute for Stem Cell Research and Regenerative Medicine. His leadership roles emphasize his commitment to fostering interdisciplinary collaboration and advancing regenerative approaches to hematologic disease. The Gottesman Institute represents a hub where stem cell biology, molecular genetics, and translational medicine converge to create innovative therapeutic strategies.
Dr. Steidl’s work is characterized by the seamless integration of cutting-edge genomic technologies, including single-cell RNA sequencing and CRISPR-Cas9 gene editing, with classical hematology. This combination allows his team to dissect the cellular heterogeneity within MDS and AML, identifying rare populations of cells that resist conventional chemotherapy and contribute to disease relapse. These findings have profound implications for the design of next-generation therapeutics capable of achieving long-term remission or cure.
Yaron Tomer, M.D., the Marilyn and Stanley M. Katz Dean at Einstein and chief academic officer at Montefiore Einstein, lauded Dr. Steidl’s induction into the AAP as a testament to his scientific rigor and translational impact. He highlighted Dr. Steidl as a physician-scientist whose research exemplifies how mechanistic studies at the molecular level can directly inform clinical practice. This bridge between bench and bedside is essential for addressing the unmet needs of patients afflicted by aggressive hematologic cancers.
More than 150 peer-reviewed publications bear Dr. Steidl’s name, illustrating the depth and breadth of his contributions to cancer biology. His research not only advances fundamental understanding but also influences clinical protocols, as several experimental therapies originating from his findings are in human trials. These trials evaluate compounds targeting aberrant survival pathways and stem cell self-renewal mechanisms, reflecting a new era of precision medicine in blood cancers.
The Montefiore Einstein Comprehensive Cancer Center, where Dr. Steidl is a deputy director, represents a model institution that merges scientific discovery with patient-centered care. NCI-designated since 1972, the center serves one of the nation’s most diverse populations, with a deliberate focus on reducing health disparities through inclusive research and community engagement. Dr. Steidl’s appointment to this leadership cadre reinforces the center’s commitment to excellence in cancer stem cell research.
Among the distinguished cohort of previous Albert Einstein College of Medicine faculty elected to the AAP are renowned physician-scientists who have made landmark contributions across various disciplines. The induction of Dr. Steidl continues this legacy of scientific achievement and highlights the institution’s role as a breeding ground for innovation in medical research.
Dr. Steidl expressed profound gratitude for the recognition, acknowledging the collaborative environment at Einstein, the inspiration derived from patients, and the support from colleagues and trainees. His statement reflects a dedication not only to advancing scientific frontiers but also to mentoring the next generation of physician-scientists who will carry forward the torch of translational research.
In sum, Dr. Ulrich Steidl’s election to the Association of American Physicians underscores his seminal role in uncovering the molecular drivers of MDS and AML, shaping new therapeutic landscapes, and exemplifying the integration of rigorous science with compassionate clinical care. His work heralds promising directions for the treatment of complex blood malignancies, emphasizing early detection and targeted intervention at the stem cell level. As the field evolves towards more personalized and effective therapies, Dr. Steidl’s discoveries continue to illuminate the path forward.
Subject of Research: Molecular and cellular mechanisms underlying myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), with emphasis on the biology of pre-leukemic and leukemic stem cells.
Article Title: Ulrich Steidl, M.D., Ph.D., Joins Association of American Physicians for Pioneering Work in Blood Stem Cell Research
News Publication Date: April 26, 2024
Web References:
- Faculty profile: https://einsteinmed.edu/faculty/11118/ulrich-g-steidl
- Montefiore Einstein Comprehensive Cancer Center: https://montefioreeinstein.org/cancer
- Albert Einstein College of Medicine: https://einsteinmed.edu
References:
- Steidl U, et al. “Myelodysplastic syndromes arise from hematopoietic stem cells with molecular defects.” Nature Medicine. 2018. https://www.nature.com/articles/s41591-018-0267-4
Image Credits: Albert Einstein College of Medicine
Keywords: Stem cell research, Cancer research, Clinical research, Hematologic malignancies, Myelodysplastic syndromes, Acute myeloid leukemia, Translational research, NIH Outstanding Investigator Award, Molecular biology, Targeted therapy, Precision medicine
